BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 22482987)

  • 1. Prenatal diagnosis of partial trisomy 16p (16p12.2→pter) and partial monosomy 22q (22q13.31→qter) associated with increased nuchal translucency and abnormal maternal serum biochemistry in the first trimester.
    Chen CP; Ko TM; Su YN; Hsu CY; Chen YY; Su JW; Chen WL; Pan CW; Wang W
    Taiwan J Obstet Gynecol; 2012 Mar; 51(1):129-33. PubMed ID: 22482987
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program.
    Krantz DA; Hallahan TW; Macri VJ; Macri JN
    Prenat Diagn; 2005 Aug; 25(8):635-40. PubMed ID: 16049986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial trisomy 16p (16p12.2→pter) and partial monosomy 22q (22q13.31 →qter) presenting with fetal ascites and ventriculomegaly: prenatal diagnosis and array comparative genomic hybridization characterization.
    Chen CP; Su YN; Young RS; Tsai FJ; Wu PC; Chern SR; Town DD; Pan CW; Wang W
    Taiwan J Obstet Gynecol; 2010 Dec; 49(4):506-12. PubMed ID: 21199755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of maternal smoking on prenatal screening for Down syndrome and trisomy 18 in the first trimester of pregnancy.
    Miron P; Côté YP; Lambert J
    Prenat Diagn; 2008 Mar; 28(3):180-5. PubMed ID: 18264956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nuchal translucency and combined test: what are the implications in clinical practice?].
    Marchini G; Rosati A; Ribiani E; Romanelli M; Porcaro G; Clerici G
    Minerva Ginecol; 2010 Jun; 62(3):187-93. PubMed ID: 20595943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
    Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
    Dugoff L; Hobbins JC; Malone FD; Porter TF; Luthy D; Comstock CH; Hankins G; Berkowitz RL; Merkatz I; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Vidaver J; D'Alton ME
    Am J Obstet Gynecol; 2004 Oct; 191(4):1446-51. PubMed ID: 15507981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
    Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
    Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
    Krantz D; Goetzl L; Simpson JL; Thom E; Zachary J; Hallahan TW; Silver R; Pergament E; Platt LD; Filkins K; Johnson A; Mahoney M; Hogge WA; Wilson RD; Mohide P; Hershey D; Wapner R;
    Am J Obstet Gynecol; 2004 Oct; 191(4):1452-8. PubMed ID: 15507982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester.
    Madsen HN; Ball S; Wright D; Tørring N; Petersen OB; Nicolaides KH; Spencer K
    Ultrasound Obstet Gynecol; 2011 Jan; 37(1):38-47. PubMed ID: 20878678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prenatal detection of trisomy 13, 18, and 21: comparison of the advanced first trimester screening (AFS) with the first trimester screening according to Nicolaides].
    Hörmansdörfer C; Schmidt P; Hillemanns P; Scharf A
    Z Geburtshilfe Neonatol; 2007 Dec; 211(6):243-9. PubMed ID: 18176905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective validation of first-trimester combined screening for trisomy 21.
    Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo monosomy 9p24.3-pter and trisomy 17q24.3-qter characterised by microarray comparative genomic hybridisation in a fetus with an increased nuchal translucency.
    Brisset S; Kasakyan S; L'Herminé AC; Mairovitz V; Gautier E; Aubry MC; Benkhalifa M; Tachdjian G
    Prenat Diagn; 2006 Mar; 26(3):206-13. PubMed ID: 16450348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal serum IGF-I, IGFBP-1 and IGFBP-3 at 11-13 weeks in trisomy 21 and trisomy 18 pregnancies.
    Sifakis S; Akolekar R; Kappou D; Mantas N; Nicolaides KH
    Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):166-8. PubMed ID: 21570171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First trimester Down's syndrome screening shows high detection rate for trisomy 21, but poor performance in structural abnormalities--regional outcome results.
    Rissanen A; Niemimaa M; Suonpää M; Ryynänen M; Heinonen S
    Fetal Diagn Ther; 2007; 22(1):45-50. PubMed ID: 17003556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10-14 weeks.
    Spencer K; Liao AW; Ong CY; Flack NJ; Nicolaides KH
    Prenat Diagn; 2001 Jul; 21(7):571-4. PubMed ID: 11494294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
    Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.